

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,  
please do not report the images to the  
**Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO,**

Copyright (c) 1993 - 2002 Compugen Ltd.

### SUMMARIES

ON protein - nucleic search, using frame\_Plus\_P2n model  
Run on: November 9, 2002, 07:31:31 ; Search time 299 Seconds  
{without alignments}  
1431.036 Million cell updates/sec

Title: US-09-895-298a-83  
Perfect score: 190  
Sequence: 1 MMNFQPPSKAWRASQQMFF.....HDGSDLRLRSRRSVOEGNPR 190  
Scoring table: OLIGO  
Xgapext 60.0 , Ygapext 60.0  
Ygapop 60.0 , Ygapext 60.0  
Fgapop 6.0 , Fgapext 7.0  
Delop 6.0 , Delext 7.0  
Searched: 2185239 seqs, 112599159 residues  
Word size: 4

Total number of hits satisfying chosen parameters:

1316744

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Command line parameters:  
-NODEL=frame+pn.model -DEV=xlp  
-DB=N\_Geneseq\_10102 -QFM=fastap -SUFFIX=oligna.rng -MINMATCH=0.1 -LOPCL=0  
-LOPEXT=0 -UNITS=bits -SPART=1 -END=-1 -MATRIX=oligo -TRANS=human40.cdl  
-LST145 -DOCALLIGN=200 -THR\_SCORE=quality -THR\_MIN=4 -ALIGN=15 -MODE=LOCAL  
-OUTFMT=pto -NORM=ext -HEARSIZE=500 -MINLEN=0 -MAXLEN=200000000  
-USER=US-09595298 @CGN 1 1.79 @unat \_06112002\_160752\_3557 -NCPU=6 -ICPU=3  
-NO\_XLPX -NO\_MMNP -LARGEQUERY -NEG\_SCORES=0 -WAIT -LONGLOG -DEV\_TIMEOUT=120  
-WARN\_TIMEOUT=30 -THRESHOLD=0 -XGAPEXT=60 -FGAPOP=6 -FGAPEXT=7  
-YGAPOP=60 -YGAPEXT=7  
- Database : N\_Geneseq\_10102/\*  
1: /SIDS2/gcgdata/geneseq/geneseq/geneseq-emb1/NA1980.DAT: \*  
2: /SIDS2/gcgdata/genetaq/geneseq/geneseq-emb1/NA1981.DAT: \*  
3: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT: \*  
4: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT: \*  
5: /SIDS2/gcgdata/genetaq/geneseq/geneseq-emb1/NA1984.DAT: \*  
6: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT: \*  
7: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT: \*  
8: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT: \*  
9: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT: \*  
10: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT: \*  
11: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT: \*  
12: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT: \*  
13: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT: \*  
14: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT: \*  
15: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT: \*  
16: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT: \*  
17: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT: \*  
18: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT: \*  
19: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT: \*  
20: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT: \*  
21: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT: \*  
22: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT: \*  
23: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT: \*  
24: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	DB	ID	Description
SUMMARIES						
1	190	100.0	1097	22	ABA0805	Human LAK-4p homolog
2	190	100.0	1097	22	AKK3221	Human polynucleotide kinase
3	190	100.0	1219	22	AAF82463	Human C4BPB411-receptor
4	190	100.0	1312	22	AKK5237	Human polynucleotide kinase
5	190	100.0	1461	21	AAA78402	Human secreted protein
6	190	100.0	1813	22	AHH18131	Human C4BPB411-receptor
7	190	100.0	1960	22	AAF82462	Human C4BPB411-receptor
8	190	100.0	2243	21	AAA61684	Human CDNA encoding a human gene
9	190	100.0	2407	22	AAF82460	Human C4BPB411-receptor
10	190	100.0	2521	22	AAF2461	Alternately spliced human gene
11	150	78.9	1194	23	ABV22463	Human prostate exp
12	150	78.9	1194	23	ABV25883	Human prostate exp
13	150	78.9	1194	23	ABV28278	Human prostate exp
14	120	63.2	470	22	AAL18919	Human breast cancer
15	110	57.9	501	22	AAL09319	Human breast cancer
c	16	71	37.4	23	ABV08852	Human prostate exp
c	17	71	37.4	23	ABV12915	Human prostate exp
c	18	52	590	23	ABV34411	Human prostate exp
c	19	52	27.4	23	ABV42908	Human prostate exp
c	20	50	26.3	22	AAH08034	Human CDNA clone
c	21	46	2.4	22	AAL19767	Human breast cancer
c	22	40	21.1	22	AAL20351	Human breast cancer
c	23	35	18.4	22	AAB58847	Human foetal liver
c	24	35	18.4	22	AKA70704	Human brain express
c	25	35	18.4	22	AKK32745	Human bone marrow
c	26	35	18.4	22	AAL13858	Human probe #7244 used to identify
c	27	35	18.4	22	ABS0743	Human genome-derived
c	28	34	17.9	22	AAL10187	Human genome-derived
c	29	32	16.8	22	AAL11452	Human genome-derived
c	30	31	16.3	22	AAL71779	Human genome-derived
c	31	31	16.3	22	AAL19896	Human brain expressed sequence tag
c	32	31	16.3	22	AAL20516	Human bone marrow
c	33	31	16.3	22	AAL15141	Human probe #20327 used to identify
c	34	31	16.3	22	ABS19993	Human genome-derived
c	35	29	15.3	23	ABV03746	Human prostate exp
c	36	16	8.4	22	AFB65737	Novel human polymerase
c	37	16	8.4	22	AAL11030	Human breast cancer
c	38	16	8.4	22	AAL18794	Human breast cancer
c	39	12	6.3	22	AAL20104	Human breast cancer
c	40	9	4.7	16	AAT25857	Human gene signature
c	41	9	4.7	22	AAS04641	Gene expression profile
c	42	9	4.7	22	ABO32690	Oligonucleotide probe
c	43	9	4.7	24	ABO32691	Human ORF X
c	44	9	4.7	21	AAC77219	Ribosomal S9 protein
c	45	9	4.7	22	AAH48003	
ALIGNMENTS						
RESULT 1						
ID	ABA08605	standard	cdNA;	1097	BP.	
XX	ABA08605					
AC	ABA08605;					
XX						
DT	11-JAN-2002	(first entry)				
DE	Human LAK-4p homologue-encoding cDNA,	SEQ ID NO:381.				
XX						
KW	haemopoiesis regulation; tissue growth; immunomodulator; activin; inhibin; chemotaxis; chemokinesis; thrombolytic; oncogenesis; proliferation; metastasis; cancer; tumour; haematopoietic disorder; myeloid cell disorder; lymphoid cell disorder; asthma; arthritis; chronic inflammatory condition; proliferative retinopathy; atherosclerosis; coronary heart disease; arterial ischaemia; bone disorder; osteoporosis; vascular growth disorder;					

**KW** tissue regeneration; wound healing; infection; immune disorder;  
**KW** cell culture; drug screening; gene therapy; antiinflammatory;  
**KW** antiasthmatic; antiarthritic; haemostatic; antiarteriosclerotic;  
**KW** cytopstatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
**KW** antifungal; vulnerary; antiulcer; ss.

**OS** Homo sapiens.

**XX**

**PN** WO20015188-A2.

**XX**

**PD** 09-AUG-2001.

**XX**

**PF** 05-FEB-2001; 2001WO-US03800.

**XX**

**PR** 03-FEB-2000; 2000US-0496914.

**PR** 27-APR-2000; 2000US-0560875.

**XX**

**PA** (HYSEQ-) HYSEQ INC.

**XX**

**PI** Tang YT, Liu C, Drmanac RN;

**XX**

**WPI:** 2001-45740/49.

**DR** P-PSDB; ABB11361.

**XX**

**PT** Human proteins and DNA encoding sequences useful for preventing, treating or ameliorating a medical condition in a mammalian subject e.g. arthritis and cancer -

**PS** Claim 1; Page 473; 1963pp; English.

**XX**

**CC** Sequences ABA10981-ABBI2330 represent 1350 novel human polypeptides, and sequences ABA08225-ABA09574 represent nucleic acids encoding them. The invention also relates to vectors and recombinant host cells comprising a nucleotide of the invention, methods of producing the novel polypeptides, antibodies against the polypeptides, methods of detecting the nucleotides or polypeptides in a sample, and methods of identifying compounds which bind to polypeptides of the invention. Although novel, many of the polypeptides of the invention have homology to known proteins, thereby giving an insight into their probable biological activities, and hence potential therapeutic applications. The polypeptides of the invention may have various activities, including cytokine, cell proliferation or cell differentiation activities; stem cell growth factor activity;

**CC** haemopoiesis regulatory activity; tissue growth activity;

**CC** immunomodulatory activity; activin; inhibin-related activities;

**CC** chemotactic or chemokinetic activities; haemostatic, thrombotic or thrombolytic activities; receptor or ligand activities; or may be involved in oncogenes, cancer cell proliferation or metastasis.

**CC** depending on their biological activities, polypeptides and nucleotides of the invention are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Such conditions include cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell disorders), chronic inflammatory conditions (e.g., asthma or arthritis), proliferative retinopathy, atherosclerosis, coronary heart disease, arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal vascular growth. Polypeptides involved with tissue regeneration and repair (or nucleic acids encoding them) may be used to promote wound healing (e.g., of burns, incisions and ulcers), while those with immunomodulatory activities may be used in the treatment of viral, bacterial and fungal infections in addition to immune disorders.

**CC** polypeptides with growth factor activity may be used in cell cultures to promote cell growth. For example, such polypeptides may be used to manipulate stem cells in culture to give rise to neuroepithelial cells that can be used to augment or replace cells damaged by illness, autoimmune disease or accidental damage. The polypeptides and nucleotides may also be used in the diagnosis of the above conditions, and in drug screening techniques. The present sequence represents a cDNA encoding a novel human polypeptide of the invention.

**SQ** Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

**Pred. No.:** 2.13e-183    **Length:** 1097    **Score:** 190.00    **Matches:** 190

---

Percent Similarity:	100.0%	Conservative:	0
Best Local Similarity:	100.0%	Mismatches:	0
Query Match:	22	Indels:	0
DB:		Gaps:	0
<b>US-09-895-298a-83 (1-190) x ABA08605 (1-197)</b>			
<b>QY</b>	1 MetMetAsnPheGlnProProSerLysAlaArgPheGlnMetMetPhePhe	20	
<b>Db</b>	259 ArgATGAAATTCCAGCCCTCGAGCAAGCTGGGGCTCACAGATGACTTC	328	
<b>QY</b>	21 IlePheLeuIleuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle	40	
<b>Db</b>	329 ATCTTCTGCTCTTTTCCCCATCTTACCGGGCTGTGGACCCCTGGCATACACATC	388	
<b>QY</b>	41 TrpArgLeuLysProSerAlaLysPheGlyProPheArgLysIleLeuPheLeuHis	60	
<b>Db</b>	389 TSGAGATGGAACCTTCAGTCAGTCAGTGCCCTTGGAGGCTGCCTCTCATCAC	448	
<b>QY</b>	61 SerIleTyrsTerTriPheAspThrLeuSerThrArgProGlyTyrLeutrpValValTrp	80	
<b>Db</b>	449 TCCATCTTACGCCGAGCACCTAAGTACAGGGCTGGCTACCGCTGGTGTGTTG	508	
<b>QY</b>	81 IleTyraArgAsnLeuIleuGlySerValHisPhePheIleLeuThrLeuLeuIleu	100	
<b>Db</b>	509 ATCTATCGAACCTCATGGAAGCTGTGCACTTCTATCTCACCCCTCATGTCATGCTA	568	
<b>QY</b>	101 IleLeuThrTyreIleuTrpGlnIlePhrGluGlyArgLysIleMetIleargLeuIleu	120	
<b>Db</b>	569 ATGATCATCACTCTTACTGCGATCAAGAGGAGGAAGAATGATAGCTTC	628	
<b>QY</b>	121 HisGluGlnIleLeuAsnGluGlyLysAspLysMetPheLeuIleGluLeuIle	140	
<b>Db</b>	629 CAGTAGCAGATCATTAATGAGGCCAAGATATAATGTCCTGATAGAAAATGTCAGA	688	
<b>QY</b>	141 LeuGlnAspMetGluLysIleAsnProSerSerLeuLeuValIleGluArgGluVal	160	
<b>Db</b>	689 CTGCAGGATGATGGAGAGAAACCCAGCTCTGTCGGAAAGGAGGTTG 748		
<b>QY</b>	161 GluGlnGlnGlyPhelauHisteLeuGlyLihisAspLysSerLeuAspLeuArgSerArg	180	
<b>Db</b>	749 GACCAACAGGCTTTCGATGGGAGACATGATGATGGCAGCTGTGACTTGCGATCTAGA 808		
<b>RESULT 2</b>			
<b>QY</b>	181 ArgSerValGlnGluGlyAsnProGala 190		
<b>Db</b>	809 AGATCAGTCAGAAAGGTAATCCAAGGGCC 838		
<b>ID</b>	AAK53221 standard; cDNA; 1097 BP.		
<b>AC</b>	AAK53221;		
<b>XX</b>			
<b>DT</b>	06-NOV-2001 (first entry)		
<b>XX</b>			
<b>DE</b>	Human polynucleotide SEQ ID NO 2750.		
<b>XX</b>			
<b>KW</b>	Human; cytokine; cell proliferation; cell differentiation; gene therapy; vaccine; peptide therapy; stem cell growth factor; haemopoiesis; tissue growth factor; immunomodulatory; cancer; leukaemia; nervous system disorder; arthritis; inflammation; ss.		
<b>KW</b>	Homo sapiens.		
<b>OS</b>			
<b>PN</b>	W020015190-A2.		
<b>XX</b>			
<b>PD</b>	09-AUG-2001.		
<b>XX</b>			
<b>PF</b>	05-FEB-2001; 2001WO-US04098.		
<b>XX</b>			
<b>PR</b>	03-FEB-2000; 2000US-0496914.		
<b>PR</b>	27-APR-2000; 2000US-0560875.		
<b>PR</b>	20-JUN-2000; 2000US-0598075.		

PR	19-JUL-2000; 2000US-060325.	PR	01-SEP-2000; 2000US-065936.	PR	141 LeuglaspMetGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
PR	15-SEP-2000; 2000US-066361.	PT	20-OCT-2000; 2000US-0693325.	PR	689 CTGGAGGATATGGAGAAGGAAACCCAGCTACTGTTCTGAAAGGAGAGGG 748
PR	30-NOV-2000; 2000US-0728422.	DR	P-PSDB; AAM80088.	PA	(HYSE-) HYSEQ INC.
XX	Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;	PI	XX	QY	161 GluGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
PI	Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;	PT	XX	QI	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
XU	Xu AJ, Yang Y, Wejhrman T, Goodrich R;	XX	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
XX	WPI; 2001-47283/51.	DR	P-PSDB; AAM80088.	DR	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
XX	Nucleic acids encoding polypeptides with cytokine-like activities, useful in diagnosis and gene therapy -	PT	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
PS	Claim 1; Page 4962; 6221pp; English.	XX	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
XX	The invention relates to polynucleotides (AAK1456-AAK53435) and the encoded polypeptides (AAM8323-AAM80302) that exhibit activity relating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polynucleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, haemopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activation/inhibition activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation.	CC	XX	Db	749 GAGCAACAAGCTTTCATGGGACATGATGGCAGTCGTGACTTGCGACTAGA 808
CC	Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666 (AAM80020) are omitted as the relevant pages from the sequence listing were missing at the time of publication.	CC	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
CC	Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;	SQ	XX	Db	809 AGTTCAGTCAGAGGAATCCAGGGCC 838
XX	Alignment Scores:	XX	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
CC	Pred. No.: 2.13e-183	CC	XX	Db	629 CATGAGCAGATCTTAATGGGCCAGATAATGTTCTGATGAGAAATTGTCAG 688
Score:	Length: 1097	Score:	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Percent Similarity: 100.00%	Matches: 190	Percent Similarity: 100.00%	XX	Db	141 LeuglaspMetGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Best Local Similarity: 100.00%	Conservative: 0	Best Local Similarity: 100.00%	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Query Match: 22	Mismatches: 0	Query Match: 22	XX	Db	689 CTGGAGGATATGGAGAAGGAAACCCAGCTACTGTTCTGAAAGGAGAGGG 748
DB:	Gaps: 0	DB:	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
XX	US-09-895-298A-83 (1-190) x AAK53221 (1-1097)	XX	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	1 MetMetAsnPheGlnProProSerLysAlaTrpGalaSerGlnMetMetThrPhePhe 20	QY	XX	Db	161 GluGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
Db	269 ATGTAAGATTCCAGCCCTGGAGCAAAGCTGGGGCCACAGATGATGACTTC 328	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Db	389 TGGAGATTGAGCCCTTCAGCTGACTGTTCTCTTCATCTAC 448	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	21 IlepheLeuLeuphepheProSerSerPheThrGlyValLeuGlyThrLeuAlaIleThrile 40	QY	XX	Db	141 LeuglaspMetGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Db	329 ATCTCTGCCTTTCCATCCATCCACGGGGCTGGCACCTGGCATCACCATC 388	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	41 TrpArgLeuIysProSerAlaAspCysGlyPropheArgGlyLeuProLeuPhelheis 60	QY	XX	Db	689 CTGGAGGATATGGAGAAGGAAACCCAGCTACTGTTCTGAAAGGAGAGGG 748
Db	389 TGGAGATTGAGCCCTTCAGCTGACTGTTCTCTTCATCTAC 448	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	61 SerIleTyrsSerPheIleAspThrLeuSerThrArgProGlyTyriLeuLeuPheValIle 80	QY	XX	Db	161 GluGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
Db	449 TCCATCTGAGCTGATGCAACCTAACGACAGCCCTACCTGTTCTGAGGTTCTG 508	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	81 IleTyryArgAsnLeuIleGlySerValHisPhePheLeuIleLeuIleLeuLeu 100	QY	XX	Db	141 LeuglaspMetGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Db	509 ATCTATCGGAACTCATCTGAGCTGACTTCCTCTTCATCTAC 568	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	101 IleLeuIleTyryLeuTyrrPheGlnIleThgIleGlyArgIleMetIleArgLeuLeu 120	QY	XX	Db	689 CTGGAGGATATGGAGAAGGAAACCCAGCTACTGTTCTGAAAGGAGAGGG 748
Db	569 ATCATCACCTATCTTACTGCGAGTCACAGGAGGAGATTATGATTAAGGCGCTC 628	Db	XX	QY	LeuGlyGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
QY	121 HisGluGlnIleLeuLeuGlyGluIysAspLeuSmetPheLeuIleGluLeuIleLeuLeu 140	QY	XX	Db	161 GluGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180
QY	Alignment Scores:	QY	XX	Db	141 LeuglaspMetGluLysLysAlaAsnProSerSerLeuValLeuLargArgGluVal 160
Pred. No.:	Length: 2.36e-183	Pred. No.:	XX	Db	689 CTGGAGGATATGGAGAAGGAAACCCAGCTACTGTTCTGAAAGGAGAGGG 748

Score:	190	Matches:	190	
Percent Similarity:	100.0%	Conservative:	0	
Best Local Similarity:	100.0%	Mismatches:	0	
Query Match:	100.0%	Indels:	0	
DB:	22	Gaps:	0	
US-09-895-298A-83 (1-190) x AAF82463 (1-1219)				
QY	1 MetMetAsnPheGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe	20	PS	
Db	4 ATGATGAATTCCAGGCCCTCGAGCAAAGCCTGGGGCCCTCACAGATGACTTCCTC	63	XX	
QY	21 IlePheLeuIlePhePheProSerPheThrGlyValLeuCysThrLeuAlaLeuThrIle	40	PI	
Db	64 ATCATCTCTCTCTCTTCCATCTTCACGGGCTCTTGACCCCTGCCCATCACATC	123	PR	
QY	41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis	60	P-PSDB; P-AM79104.	
Db	124 TGGAGATGAGCTTCAGCTGACTGCGCCCTTCAGGCTGGCCCTCTCACATC	183	DR	
QY	61 SerIleTySerIlePheAspThrLeuSerThrArgProGlyTyLeutPvAlValTrp	80	WPI; 2001-476283/51.	
Db	184 TCCATCTCTACAGCTTGATGGACACCTTAAGTACAGGGCTTGCTACTGGGGTTGTTG	243	XX	
QY	81 IleTyArgAsnIleIleIleIleSerValHisPhePhePheIleLeuThrLeuAlaLeuLeu	100	XX	
Db	244 ATCPATCGAACCTCATCGAGAGTGCACCTCTTCATCCCTCACCTCATGTGCT	303	PS	
QY	101 IleLeuThrTyLeuTyTrpGlnIleThrGluGlyArgLysIleMetIleLeuGluLeu	120	XX	
Db	304 ATCATCACTCATCTCATCTAGTGAGATCACAGAGGAGATAAGGCTGTC	363	XX	
QY	121 HisGluGlnIleLeuAspLysAspLysMetPheLeuIleGluLysLeuLys	140	CC	
Db	364 CTCAGCAGGCTCATTAATGGCCAAAGATAAAATGTCCTGTAGAAATGATCAG	423	CC	
QY	141 LeuGlnAspMetGluValLysAlaAspProSerSerLeuValLeuGluArgArgGluVal	160	CC	
Db	424 CTGAGGAGATGGAGAAGAACCCAGCTCACTGTCCTGGAAGGAGAGTG	483	CC	
QY	161 GluGlnGlyPheLeuIleLeuGlyLysIleAspGlySerLeuAspLeuArgSerGly	180	CC	
Db	484 GACGAAACAGGCTTTCATGTTGGGCAACATGATGCCAGCTGACTTGCCATAGA	543	CC	
QY	181 ArgSerValGlnGluGlyAsnProArgAla	190	CC	
Db	544 AGATCAGTCAGAAGGTTATCCAAAGGCC	573	CC	
RESULT 4			SQ	
AAK5237			Sequence 1312 BP; 370 A; 286 C; 287 G; 369 T; 0 other;	
AAK5237 standard; cDNA; 1312 BP.				
AAK5237;				
AAK5237:				
DT 06-NOV-2001 (first entry)				
XX				
DE Human polynucleotide SEQ ID NO 782.				
XX				
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;				
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;				
KW tissue growth factor; immunomodulatory; cancer; leukaemia;				
KW nervous system disorder; arthritis; inflammation; ss.				
OS Homo sapiens.				
XX				
PN WO20015190-A2.				
PD 09-AUG-2001.				
XX				
PF 05-FEB-2001; 2001WO-US04098.				
XX				
• PR 03-FEB-2000; 2000US-0496914.				
PR 27-APR-2000; 2000US-0560875.				
PA (HYSE-) HISEQ INC.				
XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;				
XX Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;				
PI Xue AJ, Yang Y, Wejhran T, Goodrich R;				
XX DR				
PT Nucleic acids encoding polypeptides with cytokine-like activities,				
PT useful in diagnosis and gene therapy -				
XX				
Claim 1; Page 2615-2616; 6221pp; English.				
The invention relates to polynucleotides (AAK51456-AAK53435) and the encoded polypeptides (AAK7833-AMB0302), that exhibit activity elating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polynucleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine-like activities, e.g. stem cell growth factor activity, hematopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation.				
Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666 (AAW0020) are omitted as the relevant pages from the sequence listing were missing at the time of publication.				
XX				
Alignment Scores:				
Pred No.:	2.53e-183	Length:	1312	
Score:	190.00	Matches:	190	
Percent Similarity:	100.0%	Conservative:	0	
Best Local Similarity:	100.0%	Mismatches:	0	
Query Match:	100.0%	Indels:	0	
DB:	22	Gaps:	0	
US-09-895-298A-83 (1-190) x AAK5237 (1-1312)				
QY	1 MetMetAsnPheGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe	20		
Db	294 ATGATGAATTCCAGCTCGAGGCAAAAGCTGGGGCTTCACAGATGACTTCCTC	473		
QY	21 IlePheLeuIlePhePheProSerPheThrGlyValLeuCysThrLeuAlaLeuThrIle	40		
Db	354 ATCTCTCTCTCTTCCATCTTCACCTCACGGGCTCTTGACCCATCACATC	413		
QY	41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis	60		
Db	414 TGGAGATGAGGCCCTCAGCTGACTGTTGGCTCTGAGGTCTCCCTCTCATTC	533		
QY	61 SerIleTySerIlePheAspPheLeuSerThrArgProGlyTyLeutPvAlValTrp	80		
Db	474 TCCATCTCTAGCTGGATCAGCCTTAAGTACGTTCTTCATCCCTCACCCATCTGTC	593		
QY	81 IleTyArgAsnIleIleIleIleIleSerValHisPhePhePheIleLeuThrLeuAlaLeu	100		
Db	534 ATCTATCGAACCTCATCTGAGCTGACTTCCTTCATCCCTCACCCATCTGTC	653		
QY	101 IleLeuThrTyLeuTyTrpGlnIleThrGluGlyArgLysIleMetIleLeuGluLeu	120		
Db	594 ATCATCACCTATCTTACTGGCAGATCACAGAGGGAGAGATGATAAGGCC	140		
QY	121 HisGluGlnIleLeuAsnGluGlyLysAspLysMetPheLeuIleGluLysLeuLys	140		

Db ||||||| 654 CATTGAGCCAGATCATTAATGAGGCCAAGATAAAATGGTCTGTAGAAATGTCAG 713  
 CC AAA78372 to AAA78380 and AAB24436 represent sequences used in the  
 CC exemplification of the present invention.  
 Qy 141 LeuGlnAspMetGluLysLysAlaasnProSerSerLeuValleuGluargGluVal 160  
 XX  
 SQ Sequence 1461 BP; 428 A; 312 C; 324 G; 397 T; 0 other;  
 Db 714 CTGCAGATGATGGAGAAAGCAACCCAGCTACTGTTCTGGAAAGGAGAGGAGG 773  
 Alignment Scores:  
 Pred. No.: 2.81e-183 Length: 1461  
 Score: 190.00 Matches: 190  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 21 Gaps: .  
 Db 834 AGATCAGTCAAGAAGGTAATCAGGGCC 863

RESULT 5  
 AAA78402  
 ID AAA78402 standard; cDNA; 1461 BP.  
 XX  
 AC  
 XX  
 DT 20-NOV-2000 (first entry)  
 XX  
 DE Human secreted protein gene 22 SEQ ID NO:32.  
 XX Human; secreted protein; cytostatic; antianaemic; antidiabetic;  
 KW antiinflammatory; ophthalmological; antirheumatic; antiarthritic;  
 KW antipsoriatic; antiangiogenic; cardiant; anti-HIV; nootropic;  
 KW neuroprotective; antimicrobial; antiparkinsonian; cancer;  
 KW immune system disorder; angiogenesis; hyperproliferative disorder;  
 KW cardiovascular disorder; apoptosis; neurological disease;  
 KW infectious disease; wound healing; ss.  
 XX Homo sapiens.  
 XX WO200035937-A1.  
 XX 22-JUN-2000.  
 PD  
 XX 16-DEC-1999; 99W0-US29950.  
 PR 17-DEC-1998; 98US-0112809.  
 PR 18-DEC-1998; 98US-0113006.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PI Ruben SM, Ebner R, Rosen CA, Endress GA, Soppet DR, Ni J;  
 PI Duan DR, Moore PA, Shi Y, Lafleur DW, Olsen HS, Florence K;  
 DR WPI: 2000-431566/37.  
 DR P-PSDB; AAB24458.

PT Forty seven human nucleic acids encoding secreted proteins, useful in  
 PT the treatment, prevention and diagnosis of cancers, disorders of the  
 PT immune system, angiogenesis disorders, neurological diseases and  
 PT hyperproliferative disorders -  
 XX  
 PS Claim 1; Page 457-458; 562pp; English.

XX  
 CC The polynucleotide sequence given in AAA78381 to AAB24604 encode the  
 CC human secreted proteins given in AAB24437 to AAB24604. Human secreted  
 CC proteins have activities based on the tissues and cells the genes are  
 CC expressed in. Examples of activities include: cytostatic; antianaemic;  
 CC antidiabetic; antiinflammatory; ophthalmological; antirheumatic;  
 CC antiarthritic; antipsoriatic; antiangiogenic; cardiant; anti-HIV;  
 CC nootropic; neuroprotective; antimicrobial and antiparkinsonian.  
 CC Human secreted protein polynucleotides, polypeptides, antagonists and/or  
 CC agonists may be useful in treating, preventing, and/or diagnosing other  
 CC diseases, disorders, and/or conditions such as: (a) cancers; (b)  
 CC disorders of the immune system; (c) angiogenesis disorders; (d)  
 CC hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases  
 CC associated with increase apoptosis; (g) neurological diseases; and  
 CC (h) infectious diseases. They are also used to promote wound healing.

Db ||||||| 161 GluGlnGlnGlyPheLeuHisLysAlaasnProSerSerLeuValleuGluargGluVal 180  
 Qy 774 GAGCAACAAGGCTTTGCAATTGGGGAACTATGATGGCGCTCTGACTGCGATCTAGA 833  
 XX  
 Qy 181 ArgSerValGluGlyLysAsnProArgAla 190  
 XX  
 DB: US-09-895-298A-83 (1-190) x AAA78402 (1-1461)

Qy 1 MetMetAsnPheGlnProProSerlysAlatPrgAlaSerGinMetMetThrPhePhe 20  
 Db 63 ATGAGTAATTCAGCTTCCASGCTCGAGATTCACCGGGCTTGTCACCCCTGGCCATCACARC 122  
 Qy 41 TrpArgLeuIleProSerSerLeuGlyValleuCysthrLeuAlaIleThrle 40  
 Db 183 TGGAGATGGAAGCCTTTCAGCTGACTGTGGCCTTTCGAGCTCTGCCTCTCACTTCAC 242  
 Qy 61 SerIleTrpSerTrpIleAspThrIleAspSerThrAspGlySerThrAspGlyTrpValValTP 80  
 Db 243 TCCAACTAACCTGATGACGACCCPAAGTACACGCCCTGCACCTGAGCTGG 302  
 Qy 81 IleTyRArgAsnLeuIleGlySerValHisPhePhePheLeuThrLeuIleValleu 100  
 Db 303 ATCTATCGAACCTCTTGGAGTGGCACTCTTATCCACCTCATGCTA 362  
 Qy 101 IleIleThrTrpLeuItrpGlnIleThrGluGlyArglysIleMetIleArgLeuLeu 120  
 Db 363 ATCATCACTACTCTTACTGGCAGATCACAGGGAGGAGATATGATAAGGGCTGC 422  
 Qy 121 HisGluGlnIleLeuGluGlyLysAspLysMetPheLeuLeuThrLeuIleValleu 140  
 Db 423 CATGAGCAGACATTTGATGAGGGAAAGATAAAATGGTCTCTGATGAAATTGTCAG 482  
 Qy 141 LeuGlnAspMetGluLysLysAlaasnProSerSerLeuValleuGluargGluVal 160  
 Db 483 CTGCAGATGATGGAGAGAAAGCAACCCAGCTACTGTTCTGGAAAGGAGAGGTG 542  
 Qy 161 GluGlnGlnGlyPheLeuHisLysAlaasnProSerSerLeuValleuGluargGluVal 180  
 Db 543 GAGCAACAAGGCTTTGCAATTGGGGAACTATGATGGCGCTCTGACTGCGATCTAGA 602  
 Qy 181 ArgSerValGluGlyLysAsnProArgAla 190  
 Db 603 AGATCAGTCAAGAAGGTAATCAGGGCC 632

RESULT 6  
 AAH18131  
 ID AAH18131 standard; cDNA; 1813 BP.  
 XX  
 AC AAH18131;  
 XX  
 DT 26-JUN-2001 (first entry)  
 XX  
 DE Human cDNA sequence SEQ ID NO:18001.  
 XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.  
 XX  
 OS Homo sapiens.  
 XX EP1074617-A2.  
 PN  
 XX PD 07-FEB-2001.  
 XX



vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases and related conditions. CASB6411 polypeptides are also useful for the structure-based design of agonists, antagonists or inhibitors of the polypeptide.

KW teratocarcinoma; autoimmune disorder; inflammatory disorder; acquired immunodeficiency syndrome; AIDS; Addison's disease; KW adult respiratory distress syndrome; allergy; ankylosing spondylitis; amyloidosis; anaemia; asthma; autoimmune haemolytic anaemia; infection; Werner syndrome; haemodialysis; extracorporeal circulation; trauma; ss.

**Alignment Scores:**  
 Pred. No.: 3.73e-183      Length: 1960  
**Score:** 190.00      Matches: 190  
**Percent Similarity:** 100.0%      Conservative: 0  
**Best Local Similarity:** 100.0%      Mismatches: 0  
**Query Match:** 100.0%      Indels: 0  
**DB:** 22      Gaps: 0  
  
**US-09-895-298A-83 (1-190) x AAFB2462 (1-1960)**

	Location/Qualifiers
XX	none defined.
FH	
FT	KEY
	CDS
FT	109..1272
FT	/*tag= a
FT	/product= "leukocyte and blood related protein (LBAP)"
FT	109..261
sig_peptide	
FT	/*tag= b
XX	
PN	WO200052161-A2.
XX	

Db 760 ATCTTCGCTGCTTACCCATCCTCACGGGTCTGACCGGCTACCCGGCATACCACTC 819  
 QY 41 TRPArgIleUlyProSerAlaAspCysGlyProPheArgGlyLeuProLeuPhelleHis 60  
 XX ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 820 TGCAGATGAAAGCTCTGAGCTGACTGAGGCCCTTTCGAGGCTGCCTCTCATCAC 879  
 QY 61 SerIleIyrSerTrpIleAspPheSerThrArgProGlyTyreutrovalValTrp 80  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 db 880 TCACTACAGCTGGATGACACCTAGTAGACAGGCTTGCTACCTGGTTGG 939  
 QY 81 IleTyraGargAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleLeu 100  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 940 ATCTATCGAACCTCATGGAATGTTGACTCTTCACCTCATGCTGCTA 999  
 QY 101 IleLeuItyrIleutTrpIleGlyLeuIleGlyIleLeuIleLeuIleLeuIleLeu 120  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1000 ATCATCACATCTTACTGGAGATCACAGGGAGAGATTAGTATAGGCCTGCTC 1059  
 QY 121 HisGluGlnIleLeuAsnGluIlyAspLysMetHeleLeuIleGluIlyLeuIleIys 140  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1060 CATGAGCAGATCATTAATGAGGCAAGATAAAATGTTCTCTGATAGAAAATGTCAG 1119  
 QY 141 LeuGlnAspMetGluIlyLysAlaAsnProSerSerIleValLeuGuArgArgGluVal 160  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1120 CTCAGAGATATGGAGAAAGCAAACCCCAGCTCACTGTTGAAAGGAGGTG 1179  
 QY 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHsAspGlySerIleLeuAspLeuIleArgSerArg 180  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1180 GAGCAACGAGCTTTCGATTTGGGACATGATGCACTTGACTGGATCTAGA 1239  
 QY 181 ArgSerIleGlnGluGlyAsnProIleAla 190  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1240 AGTCAGTCAAGAGGTAAATCCAAAGGCC 1269  
 RESULT 9  
 AAF82460  
 ID AAF82460 standard; cDNA; 2407 BP.  
 AC AAF82460;  
 XX  
 DT 29-JUN-2001 (first entry)  
 XX Human CASB6411 cDNA.  
 DE Human CASB6411 cDNA.  
 XX Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
 KW ovarian cancer; colon cancer; autoimmune disease; ss.  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 382..1764  
 FT /tag= a  
 FT /product= "CASB6411"  
 XX W0200123417-A2.  
 XX 05-APR-2001.  
 PD 27-SEP-2000; 2000WO-EP09500.  
 XX 30-SEP-1999; 99GB-0023154.  
 PR 07-JUL-2000; 2000GB-0016839.  
 XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.  
 PI Vinals De Bassols YC;  
 XX DR WPI; 2001-316133/33.  
 DR P-PSDB; AAB83079.  
 XX Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases and related conditions -  
 PT  
 PS Claim 11; Page 63-64; 95pp; English.  
 XX  
 CC The present sequence encodes human CASB6411 polypeptide. The invention relates to CASB6411 polypeptides comprising a sequence having at least 70% identity to a sequence of 460 or 154 amino acids fully defined in the specification. CASB6411 polypeptides and poly nucleotides are useful for treating a subject by immunoprophylaxis or therapy. The CASB6411 polypeptides are useful in diagnostics, and as vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases and related conditions. CASB6411 polypeptides are also useful for the structure-based design of agonists, antagonists or inhibitors of the polypeptide. The present sequence may be alternatively spliced to generate a sequence encoding a truncated CASB6411 protein.  
 CC  
 CC Sequence 2407 BP; 635 A; 557 C; 546 G; 669 T; 0 other;  
 SQ XX  
 Alignment Scores:  
 Pred. No.: 4.55e-183 Length: 2407  
 Score: 190.00 Matches: 190  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 22 Gaps: 0  
 US-09-895-298A-83 (1-190) x AAF82460 (1-2407)  
 QY 1 MetMetAsnPheGlnProProSerLysAlaTPARGAlaSerGlnMetMetThrPhePhe 20  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1192 ATGATGAAATTCGACGCCCTCGAGCAAAAGCCTGGGGCCCTCACAGATGATGACTCTTC 1251  
 QY 21 IlePheLeuIlePhePheProSerPheThrGlyValLeuCysThrLeuIleAlleleThrile 40  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1252 ATCTCTGCTCTTTCACCATCTCACCGGGCTGACCCCTGGCCATCACATC 1311  
 QY 41 TRPArgIleUlyProSerAlaAspCysGlyProPheArgGlyLeuIleLeuPhelleHis 60  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1312 TGGAGATGAAAGCCTTCAGCTGACTGTTGGCCCTTTCGAGGCTGCTTCCTCATCAC 1371  
 QY 61 SerIleIyrSerTrpIleAspPheSerThrArgProGlyTyreutrovalValTrp 80  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1372 TCCATCAGCTGAGCAGCCCTAGTACACGGCCTGCTACCTGGGTTGG 1431  
 QY 81 IleTyraGargAsnLeuIleGlySerValHisPhePheIleLeuIleLeuIleLeu 100  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1432 ATCTATGGAACTCATGCTACCTCACCTCACCCATGGCTA 1491  
 QY 101 IleLeuItyrIleutTrpIleGlySerValHisPhePheIleLeuIleLeuIleLeuIleLeu 120  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1492 ATCATCACCTCTTACTGGAGATCACAGGGAGAGATGATGAAATGCTC 1551  
 QY 121 HisGluGlnIleLeuAsnProSerSerIleValLeuLeuGluGlyLeuIleIys 140  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1552 CAGGAGCAGATCATTAGGAGGCAAGATATAATGTTCTGATGAGAAATGTCAG 1611  
 QY 141 LeuGlnAspMetGluIlyLysAlaAsnProSerSerIleLeuLeuGluGlyLeuIleIys 160  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1612 CUGCAGGATATGGAGAAAGCAACCCAGCTCACTGTTCTGAAAGGAGGTG 1671  
 QY 161 GluGlnGlnGlyPheLeuIleGluGlyGluHsAspIlySerLeuAspLeuIleArgSerArg 180  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1672 GAGCAACGAGCTTTCGATTTGGGGACATGATGCCAGCTGACTTCGACACTG 1731  
 QY 181 ArgSerIleGlnGluGlyAsnProIleAla 190  
 CC ||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1732 AGATCAGTCAAGAGGTAAATCCAAGGGC 1761  
 RESULT 10  
 AAF82461  
 ID AAF82461 standard; cDNA; 2521 BP.  
 XX  
 AC AAF82461;

XX  
 XX 29-JUN-2001 (first entry)  
 DT  
 DE Alternatively spliced human CASB6411 cDNA encoding truncated protein.  
 XX  
 KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
 KW ovarian cancer; colon cancer; autoimmune disease; isoform;  
 KW alternative splicing; ss.  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 382..846 /\*tag= a  
 FT /product= "truncated CASB6411"  
 XX WO200123417-A2.  
 XX PD 05-APR-2001.  
 XX PR 27-SEP-2000; 2000WO-EP09500.  
 XX PR 30-SEP-1999; 99GB-0023154.  
 PR 07-JUL-2000; 2000GB-0016539.  
 XX PA (SMIK ) SMTTHKLINE BEECHAM BIOLOGICALS.  
 PI vinals De Bassols YC;  
 XX WPI: 2001-316133/33.  
 DR p-PSDB; ABB83080.  
 XX PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases and related conditions -  
 PT XX PS claim 11; Page 64-65; 95pp; English.  
 XX CC The present sequence encodes a truncated CASB6411 polypeptide. It is generated by alternative splicing of the full length human cDNA sequence of CASB6411. The invention relates to CASB6411 polypeptides comprising a sequence having at least 70% identity to a sequence of 460 or 154 amino acids fully defined in the specification. CASB6411 polypeptides and polynucleotides are useful for treating a subject by immunotherapy. The CASB6411 polypeptides are useful in diagnostics, and as vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases and related conditions. CASB6411 polypeptides are also useful for the structure-based design of agonists, antagonists or inhibitors of the polypeptide.  
 CC XX SQ sequence 2521 BP; 662 A; 583 C; 583 G; 693 T; 0 other;  
 Alignment Scores:  
 Pred. No.: 4.76e-183 Length: 2521  
 Score: 190.00 Matches: 190  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 22 Gaps: 0  
 US-09-895-298A-83 (1-190) x AAF82461 (1-2521)

Qy 1 MetMetCasnPheGlnProProSerLysAlaTrpArgAlasergLlnMetMetThrPhePhe 20  
 Db 1306 ATGAGTGAATTTCAGCCTCGAGCAAGGCCUUCAGCCATCTTC 1365  
 Qy 21 IleLepheLepheLepheProSerPhePhePheGlyValLeuCystrhrLeuAlaIleThrIle 40  
 Db 1366 ATCTCTTGCTCTTTCACCCATCTCACGGGCTTGCCACCTGGCCATCACCAC 1425  
 Qy 41 TRPArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPhelIleHis 60

---

Db 1426 TGGAGATTGAGCCTCTAGCTGACTGTGCCCCCTTCGAGGTCRCCCTCTCATCAC 1485  
 Qy 61 SerIleTyrsTrpIleAspThrIleSerThrIgPrGlyTrleurnpvalValTp 80  
 Db 1486 TCCATCTACAGCTGGATGACACCCATAAGTACACGGCTCTGCTACCTGTTG 1545  
 Qy 81 IleTyrsArgasnLeuIleGlySerValIhsPhephepheIleLeuIhrIleLeuLeu 100  
 Db 1546 ATCTATGGAACTCTATTGGAGIGTGCACTCTTTCTCTCACCTCATGTGCA 1605  
 Qy 101 IleIleThrTrpLeuIlyrpGlnIleThrIgIleGluGlyArglysIleMetIleArgLeuLeu 120  
 Db 1606 ATCATCACCTACTTFACTGGCAGTCACAGAGGAGGAGATATGATAAGGGCTC 1665  
 Qy 121 HISGluGlnIleIleAsnGluGlyIysASpLySmetPheLeuIleGluIysLeuIys 140  
 Db 1666 CATGAGCAGAHCATTAATGAGGGCAAGATAAAGTCTCTGATGAAATTGATCAAG 1725  
 Qy 141 LeuGlnAspMetGluIysLysAlaAsnProSerSerLeuValLeuIgLuargGluVal 160  
 Db 1726 CTGCAGGATATGGAGAGAAACCCGAGCTACTGTCCTGAAARGGAGGAGGTG 1785  
 Qy 161 GluGlnGlnGlyPheLeuIhsIleGlyGluIhsAspGlySerLeuAspLeuIgSerArg 180  
 Db 1786 GAGCACAAGCTTTGCACTTGGGGACATGATGAGGAGCTGACTGCGATCTAGA 1845  
 Qy 181 ArgSerValGlnGluIysAspProIgala 190  
 Db 1846 AGATCAGTCAAGAAGGTAACTCAAGGGCC 1875

RESULT 11  
 ABV22463 DT 13-SEP-2002 (first entry)  
 ID ABV22463 standard; cDNA; 1194 BP.  
 XX AC ABV22463;  
 XX DT Human prostate expression marker cDNA 22454.  
 DE XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
 KW XX Pharmacogenomic marker; gene; ss.  
 OS XX Homo sapiens.  
 PN XX WO200160860-A2.  
 PD 23-AUG-2001.  
 PF 20-FEB-2001; 2001WO-US05171.  
 PR 17-FEB-2000; 2000US-183319P.  
 PR 16-MAR-2000; 2000US-189862P.  
 PR 25-MAY-2000; 2000US-207454P.  
 PR 09-JUN-2000; 2000US-211314P.  
 PR 18-JUL-2000; 2000US-219007P.  
 PR 13-DEC-2000; 2000US-255281P.  
 XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
 XX PI Schlegel R, Endege MO, Monahan JE;  
 XX DR WPI; 2001-662795/76.  
 XX PT Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer -  
 XX PS Claim 1; Page 3912; 11750pp; English.  
 XX CC The invention relates to an isolated nucleic acid molecule (I) comprising a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the specification or its complement. (I) is useful for:

CC	(a) assessing whether a patient is afflicted with prostate cancer;	XX	23-AUG-2001.
CC	(b) monitoring the progression of prostate cancer in a patient;	PD	
CC	(c) assessing the efficacy of a test compound to inhibit prostate	XX	
CC	cancer in a patient;	PF	20-FEB-2001; 2001WO-US05171.
CC	(d) assessing the efficacy of a therapy for inhibiting prostate cancer in a patient;	PR	17-FEB-2000; 2000US-183319P.
CC	(e) selecting a composition for inhibiting prostate cancer in a patient;	PR	16-MAR-2000; 2000US-189862P.
CC	(f) assessing the prostate cell carcinogenic potential of a compound;	PR	25-MAR-2000; 2000US-20754P.
CC	(g) determining whether prostate cancer has metastasized in a patient;	PR	09-JUN-2000; 2000US-211314P.
CC	(h) assessing the aggressiveness or indolence of prostate cancer in a patient;	PR	18-JUL-2000; 2000US-21907P.
CC	(I) is also useful as a pharmacodynamic or pharmacogenomic marker.	PR	13-DEC-2000; 2000US-255281P.
XX	Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;	PA	(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
SQ	Alignment Scores:	XX	
Pred. No. :	1.05e-142	Length:	1194
Score:	150.00	Matches:	150
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	78.95%	Indels:	0
DB:	23	Gaps:	0
PS		PS	Claim 1; Page 5146-5147; 11750pp; English.
XX		XX	The invention relates to an isolated nucleic acid molecule (I) comprising
QY	1 MetMetAsnPhedGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhephe	CC	a nucleotide sequence given in Tables 1-9 (ABV0010-ABV6213) of the
Db	590	CC	specification or its complement. (I) is useful for:
QY	21 IlePhetLeuLeuPhePheProSerPheThrGlyValleuCysThrLeuAlaIleThrIle	CC	(a) monitoring the progression of prostate cancer in a patient;
Db	591 ATCTCTCTGCTCTTTCACCTCACCTCACGCCATCACCC 650	CC	(c) assessing the efficacy of a test compound to inhibit prostate
QY	41 TrpArgLeuLeuProSerAlaAspCysLyIrpPheArgGlyLeuProLeuPheHis	CC	(d) assessing the efficacy of a therapy for inhibiting prostate cancer
Db	651 TGGAGATGAGGCTTCAGCTGACTGTTGAGGCTTGCTCTCATTCAC 710	CC	in a patient;
QY	61 SerIleTyrsTerTriPheAspThrLeuSerThrArgProGlyTyrsTerPhePheLeuIleLeuValleu	CC	(e) selecting a composition for inhibiting prostate cancer in a patient;
Db	711 TCCATCTCACGCGATGACACCTAACGTGAGCTGGGTGTTGG 770	CC	(f) assessing the prostate cell carcinogenic potential of a compound;
QY	81 IleTyraGasnLeuIleGlyLysSerValHisPhePhePheLeuLeuIleLeuValleu	CC	(g) determining whether prostate cancer has metastasized in a patient;
Db	771 ATCTATCGGAACCTCATTTGAAAGTGCACTRCTTTCATCCACCTCATCTGCTA 830	CC	(h) assessing the aggressiveness or indolence of prostate cancer in a patient;
QY	101 IleLeuIleTyrsTerIleTrpGlnIleThrGluGlyArgIleIleMetIleLeuGluLeu	CC	(I) is also useful as a pharmacodynamic or pharmacogenomic marker.
Db	831 ATGATCACTTAATCTTACTGGCATCACAGGGAGAGATTATGATCAGGCCTC 890	CC	
QY	121 HisGluGlnIleLeuAsnGluGlyLysAspLysMetPheLeuIleGluLysLeuIleIys	CC	
Db	891 CATGAGCAGATCTTAATGAGGCAAGATAATGTTCTGTAGATAAAATGATCAAG 950	CC	
QY	141 LeuGlnAspMetCysIleLysAlaAspPro 150	CC	
Db	951 CTGCAGGATATGGAGAAGAACCCA 980	CC	
RESULT 12		US-09-895-298a-83 (1-190) x ABV25683 (1-1194)	
ABV25683	standard: cDNA: 1194 BP.	QY	1 MetMetAsnPhedGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhephe
XX	AC	DB	591 ATCTCTCTGCTCTTTCACCTCACGCCATCACCC 650
XX	ABV25683	QY	21 IlePhetLeuLeuPhePheProSerPheThrGlyValleuCysThrLeuAlaIleThrIle
DT	16-SEP-2002 (first entry)	DB	591 ATCTCTCTGCTCTTTCACCTCACGCCATCACCC 650
DE	Human prostate expression marker cDNA 25674.	QY	41 TrpArgLeuLeuProSerAlaAspCysLyIrpPheArgProGlyTyrsTerPhePheLeuIleLeuValleu
XX	KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;	DB	711 TCCATCTCACGCGATGACACCTAACGTGAGCTGGGTGTTGG 770
XX	KW pharmacogenomic marker; gene; ss.	QY	81 IleTyraGasnLeuIleGlySerValHisPhePhePheLeuLeuIleLeuValleu
OS	O Homo sapiens.	DB	771 ATCTATCGGAACCTCATTTGAAAGTGCACTRCTTTCATCTGCTA 830
XX	PN WO200160860-A2.	QY	101 IleLeuIleTyrsTerIleTrpGlnIleThrGluGlyArgIleIleMetIleLeuGluLeu



